EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Application of intrahepatic fiducial markers in carbon ion radiotherapy for pancreatic cancer—Achieving higher precision treatment

Junya Nagata iD, Yohsuke Kusano iD, Masataka Komori, Yoshiki Takayama, Shogo Kurokawa, Atsushi Ito, Tadashi Kamada, Daisaku Yoshida, Shohei Kawashiro, Hiroyuki Katoh

Journal of Applied Clinical Medical Physics · 2026

DOI: 10.1002/acm2.70427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Applied Clinical Medical Physics, 2026. Verfasst von Junya Nagata und 9 weiteren Autor:innen. Beteiligte Einrichtung: Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Fiducial Markers, Heavy Ion Radiotherapy, Radiotherapy Planning, Computer-Assisted. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Carbon‐ion radiotherapy (CIRT) delivers highly conformal tumor doses while sparing surrounding organs‐at‐risk (OAR). However, density variations along the beam path and interfractional target motion can reduce target coverage and expose OAR to high doses. These motions are typically corrected using target matching (TM) or marker matching (MM). Because the pancreas is close to the gastrointestinal tract and major vessels, fiducial marker implantation carries a risk of organ or vascular injury, and metal artifacts from markers can affect beam range calculations. TM with computed tomography (CT) also reduces treatment efficiency and prevents real‐time motion monitoring.

Purpose

To improve pancreatic cancer CIRT by correcting interfractional target motion using fiducial markers implanted in hepatic segments 5 or 6.

Methods

Twenty patients with implanted fiducial markers who underwent liver cancer CIRT at our hospital were selected. The effect of interfractional target motion correction by MM in pancreatic cancer CIRT was evaluated as simulation study. The initial planning CT and in‐room CT images were used for bone matching (BM), liver‐dome matching (LM), TM, and MM. Correlations between target motion and fiducial marker or liver‐dome motion were analyzed, and fractional dose distributions were calculated. Variations in clinical target volume coverage (ΔCTV V95%) and OAR doses were examined across strategies per fraction.

Results

A strong correlation was observed between the motion of the target and the fiducial marker. The median ΔCTV V95% values were −4.68%, −3.97%, −1.07%, and −1.69% for BM, LM, TM, and MM, respectively. TM and MM significantly improved target coverage compared to BM and LM. OAR doses stayed within dose constraints for all methods.

Conclusion

The proposed MM approach corrected interfractional target motion, achieving target coverage comparable to TM. In pancreatic cancer CIRT, managing gastrointestinal gas and body contour changes along with tumor motion may further optimize target coverage and improve clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsFiducial MarkersHeavy Ion RadiotherapyRadiotherapy Planning, Computer-AssistedHumansRadiotherapy DosageOrgans at RiskTomography, X-Ray ComputedRadiotherapy, Intensity-ModulatedMaleFemale

Stichwörter der Autor:innen

Carbon‐ion radiotherapyinterfractional motionin‐room CTmarker matchingpancreatic cancer

Autor:innen und Institutionen

  • Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
  • Section of Medical Physics and Engineering, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
  • Department of Radiation Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.

ORCID-Profile: Junya Nagata, Yohsuke Kusano

Zitieren

APA

Nagata, J., Kusano, Y., Komori, M., Takayama, Y., Kurokawa, S., Ito, A., Kamada, T., Yoshida, D., Kawashiro, S., & Katoh, H. (2026). Application of intrahepatic fiducial markers in carbon ion radiotherapy for pancreatic cancer—Achieving higher precision treatment. Journal of Applied Clinical Medical Physics. https://doi.org/10.1002/acm2.70427

Vancouver

Nagata J, Kusano Y, Komori M, Takayama Y, Kurokawa S, Ito A, et al. Application of intrahepatic fiducial markers in carbon ion radiotherapy for pancreatic cancer—Achieving higher precision treatment. Journal of Applied Clinical Medical Physics. 2026. doi:10.1002/acm2.70427

BibTeX
@article{Nagata2026,
  author = {Nagata, Junya and Kusano, Yohsuke and Komori, Masataka and Takayama, Yoshiki and Kurokawa, Shogo and Ito, Atsushi and Kamada, Tadashi and Yoshida, Daisaku and Kawashiro, Shohei and Katoh, Hiroyuki},
  title = {Application of intrahepatic fiducial markers in carbon ion radiotherapy for pancreatic cancer—Achieving higher precision treatment},
  journal = {Journal of Applied Clinical Medical Physics},
  year = {2026},
  doi = {10.1002/acm2.70427}
}
Kostenlos starten →